Bulletin 50: Pregabalin in neuropathic pain is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.
Across the PrescQIPP membership (approximately 16.4 million patients) over £60 million is spent annually on pregabalin (ePACT May 2013). This bulletin reviews the place in therapy of neuropathic pain treatments and offers guidance and support material for organisations considering reviewing pregabalin and gabapentin prescribing as a QIPP project. It supports the implementation of NICE Clinical Guideline 173.